The medical community’s understanding of lung cancer has become increasingly sophisticated in recent years and, as a result, significant advancements have been seen in targeted therapies for this patient population.
Professional organizations such as the National Comprehensive Cancer Network (NCCN) have remained at the forefront of testing and treatment paradigms based on the latest available data and drug approvals. Guidelines from NCCN for non-small cell lung cancer (NSCLC) are among the most frequently updated, with seven revisions in 2021 alone. While this speaks to the speed of the evolving landscape, it can also create proverbial whiplash among providers of lung cancer patients as they navigate the multitude of testing and treating options available to them.
This white paper from NeoGenomics compares lung cancer biomarker testing rates in the community practice setting with NCCN guidelines, discussing the implications of current testing algorithms on time-to-treatment and tissue availability and how real-world lab data provides evidence-based rationale for building precision oncology programs.